Hair loss in men and women is a list of complex causes, from genetic predisposition and androgen imbalances to physical and mental stress and covide-19. In response, the scope of practice and treatment options is expanding exponentially. However, not all of these therapies are equally effective and safe, at the SCALE Symposium Music and Music Center in Nashville, Tennessee, August 18-22, 2021, Nashville, Tennessee.1
This track outlines some of the most promising treatments, how to choose and use these options, and how to prepare for the more covide-related effects of hair loss as the epidemic enters a new phase.
The potential of Harnes’ regenerative medicine
Rehabilitation therapy is “amazing”, it has unparalleled potential as pop therapy, says Michael H. Gold, MD, co-founder of the Gold Skin Care Center, at the Center for Advanced Aesthetics Medical Spa, Laser and Rejuvenation Center and the Tennessee Clinical Research Center in Nashville, Tennessee, during a presentation on hair loss at the SCALE Conference.2,3 But he warned that this could be lost if dermatologists do not do deep homework.
For example, gold has been shown to be a major role in platelet-rich plasma (PRP) in dermatology and although it has shown positive results in other cosmetic procedures, the technique has proven to be a very effective treatment for hair loss.
Although an increasing number of PRP kits claim that their products are high on the shelf, Gold says that some do not support their position with peer-reviewed studies, publications and proven scientific research. The FDA has cut off fake-science products, but doctors say they should still be careful about which PRP products they choose.
“The products we choose should be supported by sound science, which is best done by specialized dermatologists and / or clinicians in the field of hair and hair loss,” said Gold. “I believe the beauty and dermatology companies out there are slowly realizing that we as medical professionals want this for our patients.”
According to Gold, over-the-counter medications such as finasteride, non-prescription drugs such as monoxide, special diets — including high-protein, vitamin D, biotin, and iron supplements — may be helpful in treating alopecia.
Neutral products have proven effective in preventing hair loss and helping hair grow back, says Gold. However, physicians are advised to seek out well-balanced products from reputable companies and use products supported by Plassebo-controlled clinical trials, including hair growth, to respond to their claims.
In addition, more innovations are on display. In July, the FDA cleared the new drug testing (NDA) application for Kintor Pharmaceutical Fiction GT20029 for androgenetic alopecia (AGA) and acne. The GT20029 is the first PROTAC combination of local proteolysis targets that has entered the clinical picture globally.
“Hair loss treatment is a very widespread business today and is promising for most men and women with Alzheimer’s, PRP, nutritional diets and other tuberculosis patients,” Gold said. If you want to be in the rehabilitation area, no matter what the injection, typhoid or medicine, you have to do it. [your] Homework. “
Kovid-19 and hair loss
Hospital patients with CVD-19 and androgenetic alopecia are more likely to be in the control group than in older age groups, and the main pathology may be due to androgens, according to Applied Biology, Inc. Chief Medical Officer Andy Goren said. ., In Irvine, California, on his presentation on SCALE Hair Loss.4
Recent data suggest that patients with high tissue androgen levels may suffer from severe covarial symptoms according to gore. This finding led to clinical trials of the CV-19 genetic and androgen evaluation. Some of the key findings include the use of anti-androgen hormones, particularly and CVD-19, androgen deprivation therapeutic drugs.
In his study of hair loss, Goren noted that male patients had a disproportionate effect compared to female patients, but prenatal infants were less likely to be affected. In his view, this seems to indicate an androgen level imbalance in infected individuals.
Androgens play a major role in hair loss but not in COVID effluvium. “The stress associated with the epidemic can cause telogen influenza, or covide influenza, which in no way causes the hair to turn into normal hair growth,” says Goren.
Recent research has shown a link between the androgen response and coronavirus. Goren and his team discovered that the SARS COVID-2 enzyme was needed to enter the lung type II pneumocytes, specifically TMPRSS2.
“The only known stimulant in humans is the enzyme regulator that regulates the androgen response and this has improved our focus on androgens and androgen receptors, which is the first thought in androgenetic alopecia,” Goren said.
In 2 consecutive observational studies5-6Goren and colleagues found that men with CV-19 who had the virus had less hair than the patient. As a result, baldness has been identified as a major risk factor for covad-19 infection, reaffirming the fact that epilepsy-related hair loss is not associated with anxiety but with androgens.
This finding led to the hypothesis that androgen receptor genetics — how androgens are obeyed — could predict the risk of covide-19 severity.
“From a dermatological point of view, this discovery was accidental and exciting because the relationship between baldness and androgenetic conditions seems to have influenced the severity of CVD-19 disease. “However, it is not surprising that the influenza virus is thought to be affected by androgens. In fact, studies show that androgens reduce the effectiveness of the vaccine.
In a retrospective analysis, researchers began working with Covide-19 potential treatment for dual 5-alpha-reductase inhibitor dutasteride and studied the effects of the drug in patients who had been taking the drug for more than 6 months – with a protective effect – compared to those who did not.
Following the positive results of the analysis, the researchers turned to the use of the drug and androgen deprivation therapy in patients admitted to Cowid-19 Hospital, which provides a more potent and rapid action to reduce androgens in the body.
Proxalutamide (Kintor Pharmecuticals), a second-generation androgen receptor antagonist, as well as HC-1119 (Hinova Pharmaceuticals), androgen receptor inhibitor, are currently used in CVD-19 patients in stage 3 trials (NCT04728802 and NCT064981). If approved by the FDA, these drugs could represent a completely new treatment for covad-19 infection, Goren said.
According to the study, Goren suggested that patients with hair loss consult a dermatologist, which may indicate a high risk of covide-19. He concluded by saying that a holistic approach would be the best way to provide better patient care.
Goren and Gold did not report any related financial statements.
- Gold MH, Goren A, Fisher J, and more. SCALE Hair Workshop The full cycle of managing a hair loss patient. Presented at the 16th Annual Meeting of the Fishing Music City SCALE; August 18-21, 2021, in Nashville, Tennessee.
- Gold MH PRP updates. Presented at the 16th Annual Meeting of the City Music Festival; Aug. 18-21, 2021, Nashville, Tennessee
- Gold MH Hair Loss Treatments: Nutrition and New Medical Therapy. Presented at the 16th Annual Meeting of the City Music Festival; Aug. 18-21, 2021, Nashville, Tennessee
- Goren, a. What is new in hair research, including covide updates? Presented at the 16th Annual Meeting of the Fishing Music City SCALE; August 18-21, 2021
- Goren A, Vano-Galvan S, Wombier CG, and more. Preliminary observations in Spain’s men’s hair loss among covid-19 patients – a hint of the role of androgen in covide-19 severity. J. Cosmet Dermatol. 2020 July, 19 (7) ፡ border1545-1547. doi: 10.1111 / jocd.13443. April 2020 April 23.
- Wambier CG, Vaño-Galván S, McCoy J, and others. Androgenetic alopecia is found in most patients in CVD-19 in the hospital. J Am Acad Dermatol. 2020 August; 83 (2): 680-682. doi: 10.1016 / j.jaad.2020.05.079. Heb 2020 May 22.